Professor Sanjay Gandhi
North Bristol NHS Trust
Professor Sanjay Gandhi is Radiology Training Lead at the University of Bristol. He is Research and Innovation Lead for Core Clinical Service at the largest teaching NHS trust in South West England.
Professor Gandhi has published several research papers and Editorials on the use of high-tech medicine to improve patient care. He is an internationally recognised figure in the development of the new generation of PACS, Computer Aided Diagnosis and eLearning tools and regularly delivers conference talks in the USA and Europe. In 2008, he established a new lecture programme with the University of West of England to teach latest innovations. He has been an Advisor to a number of medium to large multinational organisations.
Professor Gandhi has contributed to the development of the UK’s National Imaging Guidelines and has Co-authored and Edited 8 medical textbooks, which have won several awards including the British Medical Association’s ‘Highly Commended Editor’ award.
Role of CAD and AI in lung and colorectal cancers
Computer Aided Detection and automated image analysis are becoming more affordable and reliable. CAD is increasingly used in the assessment of many medical conditions including colorectal polyps and lung nodules. Further potential uses include quantification of metastatic disease and follow-up. Our research and other studies show a wide variation in the performance of commercially available tools. We will discuss the current role of CAD & AI, common pitfalls and new developments.
EVEN MORE SEMINARS
Richard Edwards BSc MBBS FRCS FRCS MD Circle Bath Hospital
Mr Naga Venkatesh Jayanthi MD, FRCS Bupa - Consultant Surgeon
Minimal Invasive Oesophagectomy – where are we going?
Imran Liaquat MBChB BSc MedSci MRCS FRCS MEd NHS Lothian, Scotland
Optimising Surgical Resection in Low Grade Glioma Patients
Rob Duncombe The Christie NHS Foundation Trust
Medicine Optimisation in Oncology. How to achieve best value.
Philip Beer MRCP, FRCPath, PhD ONCODNA S.A
The evolution of oncology therapeutics in the genomic era.